Sanofi (SNY +0.8%) reported positive results for its MS drug Lemtrada late yesterday, saying it...


Sanofi (SNY +0.8%) reported positive results for its MS drug Lemtrada late yesterday, saying it remained effective during the first year of an extension study. The data "really speaks to Lemtrada's unique approach to disease modification," says the company's Michael Panzara, speaking at a Neurology conference. An under-the-radar way to play Lemtrada's success is discussed in this SA Pro article.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs